Champions Oncology (CSBR) Payables (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Payables of $6.9 million for Q2 2026, up 62.5% year-over-year from $4.2 million in Q2 2025, and up 20.56% quarter-over-quarter from $5.7 million in Q1 2026.
Champions Oncology (CSBR) Payables (2011 - 2026) Analysis & Trends
Champions Oncology's Payables history runs 16 years deep, the most recent figure standing at $6.9 million for Q2 2026.
- In Q2 2026, Payables rose 62.5% year-over-year to $6.9 million; the TTM figure through Apr 2026 stood at $6.9 million (up 62.5% YoY), while the FY2026 annual figure was $6.9 million, up 62.5% from the prior year.
- Payables for Q2 2026 stood at $6.9 million, up from $5.7 million in the prior quarter.
- The five-year high for Payables was $6.9 million in Q2 2026, with the low at $2.5 million in Q3 2022.
- The 5-year median for Payables is $4.8 million (2024), against an average of $4.8 million.
- The sharpest annual moves came in 2023 and 2025: Payables surged 127.0% in 2023, then dropped 26.76% in 2025.
- Champions Oncology's Payables stood at $4.6 million in 2022, then declined by 1.5% to $4.5 million in 2023, then gained by 7.01% to $4.9 million in 2024, then increased by 23.47% to $6.0 million in 2025, then climbed by 15.18% to $6.9 million in 2026.
- Business Quant data shows CSBR's Payables at $6.9 million in Q2 2026, $5.7 million in Q1 2026, and $6.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 6.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 6.90 Mn |
| Jan 31, 2026 | 5.73 Mn |
| Oct 31, 2025 | 5.99 Mn |
| Jul 31, 2025 | 4.85 Mn |
| Apr 30, 2025 | 4.25 Mn |
| Jan 31, 2025 | 5.09 Mn |
| Oct 31, 2024 | 4.85 Mn |
| Jul 31, 2024 | 5.24 Mn |
| Apr 30, 2024 | 5.80 Mn |
| Jan 31, 2024 | 4.76 Mn |
| Oct 31, 2023 | 4.54 Mn |
| Jul 31, 2023 | 5.76 Mn |
| Apr 30, 2023 | 5.33 Mn |
| Jan 31, 2023 | 4.30 Mn |
| Oct 31, 2022 | 4.61 Mn |
| Jul 31, 2022 | 2.54 Mn |
| Apr 30, 2022 | 2.87 Mn |
| Jan 31, 2022 | 3.74 Mn |
| Oct 31, 2021 | 3.48 Mn |
| Jul 31, 2021 | 3.35 Mn |